Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FX06 for COVID-19 ARDS
NCT04618042Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2020
- Primary completion
- May 2021
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of FX06 in COVID-19 pneumonia, acute respiratory distress syndrome (ARDS), sponsored by Assistance publique - Hôpitaux de Paris. Started Nov 2020; status: completed.
02
Drugs
FX06
03
Conditions
COVID-19 pneumoniaacute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04618042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04618042.